The strong allogeneic response to donor MHC molecules in transplantation and the weak response to tumor antigens represent two important and divergent but potentially interactive immune responses.

5 Preclinical studies of VLPs-based tumor antigen delivery platform Tumor cells can evade the recognition of the immune system through various means, thereby achieving immune tolerance. The ultimate ...

Receptors on the surface of cytotoxic T cells recognize peptides presented by major histocompatibility complex (MHC) molecules on the tumor cell membrane. CD8 acts as a T-cell co-receptor that ...

However, for patients with ‘cold’ tumors that express low levels of tumor-infiltrating ... a broad swath of tumor antigens to the immune system and prime T cell recognition of these antigens.

In a recent study published in Nature Biotechnology, researchers describe the molecular structure of targeted recognition ... including tumor-associated antigens or neoantigens, as well as ...

Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...

Department of Pathology, UMass Chan Medical School, Worcester, Massachusetts.

Dr. Won Jin Ho presented a talk as part of the Immunology Neighborhood Seminar on “Overcoming the tumor immune ...

(2) These cells are activated using anti-CD3/CD28 antibodies to stimulate their proliferation. (3) Genetic modification of the T cells is performed by inserting the CAR gene, enabling them to ...